Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
Volume: 14, Issue: 1, Pages: e1005924 - e1005924
Published: Jan 2, 2018
Abstract
Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little efficacy in the clinic, partly because of inappropriate dosing. Here, we developed a computational approach to model the in vitro cellular dynamics of...
Paper Details
Title
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
Published Date
Jan 2, 2018
Journal
Volume
14
Issue
1
Pages
e1005924 - e1005924
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History